When tidal waves come in the equities markets, the last thing you want to do is try to fight it. At Portfolio Wealth Global, we do a lot of things but you’ll never catch us swimming against the tide when it comes to investing. Sure, we’re contrarians at heart, but when a sea change happens, it’s either time to ride the wave or get off the beach.
So where is the tide shifting to right now? Finding market trends in their beginning stages is my specialty, and right now I see the legalized medical cannabis industry as the wave of the future.
It’s a global phenomenon, but some regions of the world are better positioned than others; California, for example, is a progressive state when it comes to marijuana legalization.
Companies that get involved and create strong, profitable alliances in this region tend to outperform and are best positioned to reward investors handsomely.
The California cannabis market has been my specific target for its rich growth potential. Research shows a projected compound annual growth rate of 23% in this niche:
Courtesy of New Frontier Data and Arcview Market Research
California has low patient barriers to cannabis access, a long cannabis industry history, and in the northern part of California we find the most extensive legalized marijuana cultivation and production region in the nation. To put it succinctly, when it comes to the U.S. cannabis market, California is the right place, and now is the right time.
Since it has such a large population along with a cannabis-friendly attitude, it should come as no surprise that California already has the infrastructure in place for the legalized medical cannabis market to hit the ground running. And if you’re ready to ride the massive, unstoppable wave of marijuana legalization in the United States, the smaller states just don’t come close to what’s going on in California:
Courtesy of Matt Karnes, GreenWave Advisors
This is a region that dwarfs all the others, both in market size and in profit potential. What the research experts at Portfolio Wealth Global have been painstakingly searching for, therefore, is a firm that is based in California and really understands the medical cannabis market there.
It look a long time and all of our resources, but we finally came up with the perfect way to play it: Fincanna Capital Corp. (CSE: CALI, OTC: FNNZF), a royalty company specifically focused on the California medical cannabis industry.
Fincanna’s mission is to combine extensive investment expertise and industry experience in funding best-in-class businesses in the American licensed medical cannabis industry – and they’ve chosen the best place in the nation and in the world to accomplish this.
Fincanna works closely with these firms, aligning the business and financial interests of existing owners and operators with those of FinCanna. This model of royalty financing is the perfect alternative to old-school paradigms of debt and equity financing.
Fincanna’s president and CEO, Andriyko Herchak, is leveraging his 20 years of executive leadership experience with publicly traded companies to catapult Fincanna to the top. Key partnerships will make the difference here, as Mr. Herchak has aligned Fincanna with the best firms in the business.
Just one example would be FinCanna’s partnership with; Fincanna will receive a perpetual royalty equal to 10% of Green Compliance’s gross revenues, with their state-of-the-art enterprise compliance and point-of-sale software solution (“ezGreen”) for licensed medical cannabis dispensaries and cultivators. As another example, Fincanna will receive a tiered corporate royalty ranging from 7.5% to 14% of the revenues of Gram Co Holdings, a company that has leased a facility in Oakland, California in which they are retrofitting a large, state-of-the-art medical cannabis extraction laboratory expected to be operating by the end of 2018.
And just recently, things have gotten even better: Fincanna has executed an Expanded Royalty Agreement with Refined Resin Technologies Inc. Located in Oakland, California, Refined Resin Technologies is a cannabinoid research and refinery company that provides B2B and B2C products and services to licensed dispensaries and distributors in the medical cannabis supply chain. Because of this agreement, FinCanna will receive a tiered corporate royalty ranging from 5% to 14% of Refined Resin Technologies’ annual revenues.
This is a win-win situation, as Refined Resin’s principals have extensive experience in extraction, manufacturing, and business operations throughout California.
The best way to describe this company is severely undervalued and dominant in the California medical cannabis market. Visionary leadership and long-term strategic partnerships will continue
Legal Notice: Never base any decision off of our advertorials. Portfolio Wealth Global stock profiles are intended to be stock ideas, NOT recommendations. The ideas we present are high risk and you can lose your entire investment, we are not stock pickers, market timers, investment advisers, and you should not base any investment decision off our website, emails, videos, or anything we publish. Please do your own research before investing. It is crucial that you at least look at current public filings and read the latest press releases. Information contained in this profile was extracted from current documents filed with the public, the company web site and other publicly available sources deemed reliable. Never base any investment decision from information contained in our website or emails or any or our publications. Our report is not intended to be, nor should it be construed as an offer to buy or sell, or a solicitation of an offer to buy or sell securities, or as a recommendation to purchase anything. This publication may provide the addresses or contain hyperlinks to websites; we disclaim any responsibility for the content of any such other websites. We are long FinCanna Capital Corp. and own shares of the company that we will not sell during our active marketing coverage. The company has paid two hundred and fifty thousand Canadian dollars for one year of digital advertising, which includes emails, videos, and interviews. Please use our site as a place to get ideas. Enjoy our videos and news analysis, but never make an investment decision off of anything we say.
Please read our full disclaimer at PortfolioWealthGlobal.com/Disclaimer
Research Partner, PortfolioWealthGlobal.com